3.0
Apr 21, 2021
Recommend
CEO approval
Business Outlook
Pros
Has been a company dedicated to patient and clinical trial submissions
Cons
Has, do some degree, lost sight of the people in the company have been dedicated to the promotion of clinical trial data submissions